Complete Guide to ORKA-002 Pharmacokinetics
Overview
ORKA-002 is a IL-17A/IL-17F monoclonal antibody used in the Immunology/Dermatology therapeutic area. It is indicated for Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. Interactive bimekizumab (BIMZELX) pharmacokinetic simulator based on FDA label population PK, with plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa regimens.
Mechanism of Action
ORKA-002 exerts its pharmacological effect by targeting IL-17A and IL-17F. As a IL-17A/IL-17F monoclonal antibody, it modulates this target to achieve therapeutic efficacy in Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published 1-compartment SC PopPK models for ORKA-002:
| Parameter | Value |
|---|---|
| F | 0.7 |
| V L | 7.84 |
| KA per day | 1.043 |
| CL L per day | 0.2359 |
| half life days | 23 |
| hs v multiplier | 1.18 |
| hs cl multiplier | 1.31 |
| weight exponent v | 1 |
| weight exponent cl | 1.11 |
| reference weight kg | 87 |
| single dose tmax days | 3.5 |
| single dose cmax ug per ml | 25.7 |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
ORKA-002 is administered via the Subcutaneous route. Subcutaneous administration provides sustained absorption from the injection site. Bioavailability and absorption rate may vary by injection site and volume.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Immunology/Dermatology therapeutic area, for the treatment of Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa, understanding the pharmacokinetics of ORKA-002 is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect ORKA-002 pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive ORKA-002 PK Simulator
Explore ORKA-002 pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of ORKA-002?
The elimination half-life of ORKA-002 depends on patient-specific factors. Use our interactive ORKA-002 PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is ORKA-002 administered?
ORKA-002 is administered via the Subcutaneous route. It is indicated for Moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. As a IL-17A/IL-17F monoclonal antibody, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of ORKA-002?
Key pharmacokinetic parameters for ORKA-002 include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate ORKA-002 dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive ORKA-002 PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.